STERIS plc (NYSE:STE – Free Report) – Analysts at Zacks Research decreased their Q2 2025 earnings per share estimates for shares of STERIS in a research report issued on Wednesday, July 31st. Zacks Research analyst R. Department now anticipates that the medical equipment provider will post earnings per share of $2.22 for the quarter, down from their previous forecast of $2.31. The consensus estimate for STERIS’s current full-year earnings is $9.16 per share. Zacks Research also issued estimates for STERIS’s Q3 2025 earnings at $2.38 EPS, Q4 2025 earnings at $2.62 EPS, FY2025 earnings at $9.22 EPS, Q3 2026 earnings at $2.32 EPS, Q4 2026 earnings at $3.06 EPS and FY2026 earnings at $10.06 EPS.
Other research analysts have also issued research reports about the stock. JMP Securities reiterated a “market outperform” rating and issued a $265.00 price objective on shares of STERIS in a research note on Friday, July 26th. Needham & Company LLC reiterated a “hold” rating on shares of STERIS in a report on Friday, May 10th. StockNews.com cut STERIS from a “buy” rating to a “hold” rating in a report on Monday. Finally, Piper Sandler reissued a “neutral” rating and issued a $225.00 target price (up from $220.00) on shares of STERIS in a report on Friday, May 10th. Four equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $241.60.
STERIS Stock Performance
Shares of STE opened at $239.27 on Monday. The company has a 50-day moving average of $224.64 and a two-hundred day moving average of $222.69. The stock has a market cap of $23.65 billion, a price-to-earnings ratio of 62.64 and a beta of 0.83. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.08 and a quick ratio of 2.36. STERIS has a one year low of $195.47 and a one year high of $243.19.
STERIS (NYSE:STE – Get Free Report) last released its earnings results on Wednesday, May 8th. The medical equipment provider reported $2.58 EPS for the quarter, topping analysts’ consensus estimates of $2.41 by $0.17. STERIS had a net margin of 6.95% and a return on equity of 13.73%. The business had revenue of $1.42 billion for the quarter, compared to the consensus estimate of $1.41 billion. During the same period in the previous year, the firm earned $2.30 EPS. The business’s revenue for the quarter was up 10.8% on a year-over-year basis.
STERIS Increases Dividend
The firm also recently declared a quarterly dividend, which will be paid on Friday, September 20th. Investors of record on Thursday, September 5th will be given a dividend of $0.57 per share. This represents a $2.28 dividend on an annualized basis and a dividend yield of 0.95%. This is an increase from STERIS’s previous quarterly dividend of $0.52. The ex-dividend date is Thursday, September 5th. STERIS’s dividend payout ratio (DPR) is presently 59.69%.
Insiders Place Their Bets
In related news, VP Renato Tamaro sold 1,154 shares of the business’s stock in a transaction that occurred on Thursday, May 16th. The shares were sold at an average price of $231.64, for a total transaction of $267,312.56. Following the completion of the transaction, the vice president now owns 6,677 shares of the company’s stock, valued at $1,546,660.28. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In other news, SVP Cary L. Majors sold 2,024 shares of the stock in a transaction dated Monday, May 13th. The shares were sold at an average price of $232.13, for a total transaction of $469,831.12. Following the completion of the sale, the senior vice president now directly owns 11,369 shares in the company, valued at $2,639,085.97. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, VP Renato Tamaro sold 1,154 shares of the firm’s stock in a transaction dated Thursday, May 16th. The stock was sold at an average price of $231.64, for a total transaction of $267,312.56. Following the completion of the sale, the vice president now owns 6,677 shares of the company’s stock, valued at $1,546,660.28. The disclosure for this sale can be found here. Insiders sold 7,762 shares of company stock valued at $1,798,477 over the last ninety days. 1.14% of the stock is currently owned by insiders.
Hedge Funds Weigh In On STERIS
Several large investors have recently made changes to their positions in the business. First Personal Financial Services purchased a new position in STERIS in the 1st quarter worth about $25,000. J.Safra Asset Management Corp increased its position in shares of STERIS by 77.9% during the 1st quarter. J.Safra Asset Management Corp now owns 121 shares of the medical equipment provider’s stock valued at $27,000 after purchasing an additional 53 shares during the last quarter. Quent Capital LLC increased its position in STERIS by 112.7% during the first quarter. Quent Capital LLC now owns 134 shares of the medical equipment provider’s stock valued at $30,000 after acquiring an additional 71 shares during the last quarter. VisionPoint Advisory Group LLC purchased a new position in STERIS in the 4th quarter worth about $34,000. Finally, Headlands Technologies LLC bought a new stake in STERIS during the 1st quarter valued at $36,000. 94.69% of the stock is currently owned by hedge funds and other institutional investors.
About STERIS
STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.
Featured Articles
- Five stocks we like better than STERIS
- The How and Why of Investing in Gold Stocks
- Uber’s Earnings Beat: Rideshare and Delivery Surge
- 3 Warren Buffett Stocks to Buy Now
- Hims & Hers Reports Stellar Quarter: Stock Set for a Rally
- Top Stocks Investing in 5G Technology
- Cloudflare Stock Flares Up on Solid EPS Beat and Raised Guidance
Receive News & Ratings for STERIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STERIS and related companies with MarketBeat.com's FREE daily email newsletter.